

News

10 October 2005

**CURIDIUM ANNOUNCES EXCITING COMMERCIAL OPPORTUNITIES
FROM NEW RESEARCH
IN SCHIZOPHRENIA AND BIPOLAR DISORDER
Discoveries highlighted on launch of new company website**

London, England (10 October 2005): Curidium Limited, a private UK-based biotechnology company focused on drug development for Central Nervous System (CNS) disorders, today announced prominent new research results in psychiatric diseases. The Company's latest research concerns the identification of different patient sub-populations each having a distinct causative mechanism underlying the disease. This provides Curidium with innovative approaches to both the diagnosis and treatment of psychiatric diseases. The Company has launched a new website highlighting its recent developments.

Founded in 2001 by individuals with a strong track record in the pharmaceutical and biotechnology industry and focused on the discovery, development and sales of CNS drugs, Curidium has pioneered Homomatrix™, a novel approach to the analysis of genomic and biological data from disease-affected and control subjects. The application of Homomatrix™ can reveal a previously unknown role of a drug target in a disease and may result in the identification of novel therapeutic applications for existing, safe drugs.

Through the successful application of this technology to schizophrenia and attention deficit hyperactivity disorder (ADHD), the Company has already discovered two exciting drug development opportunities. Now, in an in-depth analysis of schizophrenia and bipolar disorder at the whole genome level, Curidium has established that patients may be identified and sub-grouped on the basis of distinguishing disease mechanisms. The Company has filed a patent application which, it believes, captures an important area for the development of targeted medicines for schizophrenia and bipolar disorder. With the potential to impact on initiatives worldwide aimed at better patient stratification, these discoveries stand to greatly improve success and patient compliance rates with current and future drug treatments.

Dr. Anne Bruinvels, Founder and Chief Executive Officer of Curidium commented:

"Our goal from the very beginning with Curidium has been to build a deep understanding of a disease, its causes and subtypes, as the foundation to develop safe and effective drugs for patient sub-groups. The large-scale application of Homomatrix™ to psychiatric disorders has given us an unprecedented insight into the causative mechanisms and patient sub-populations. But above all, this has provided us with a wide range of exciting, new therapeutic and diagnostic opportunities, which may shape the future of psychiatric medicine."

Curidium is seeking to partner certain of these opportunities with CNS focused pharmaceutical and biotechnology companies.

For other recent developments at Curidium, please visit the Company website at <http://www.curidium.com>.

-ENDS-

For more information about Curidium, please contact:

Dr. Anne T. Bruinvels, CEO

Curidium Ltd.
Hamilton House
Mabledon Place
London,,WC1H
9BB
United Kingdom
Phone: +44 (0)20 7554
8790
Fax: +44 (0)20 7554
8791
E-mail: info@curidium.com

Curidium Medica plc © 2002-2005

Hamilton House, Mabledon Place, London WC1H 9BB, United Kingdom.

Email: info@curidium.com Tel.: +44 (0)20 7554 8790, Fax: +44 (0)20 7554 8791